LCTX · Lineage Cell Therapeutics, Inc. · Debt
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Finance lease liabilities | 2026-06-30 | USD 48,000 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 2,251,000 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.